Anti-RNPC-3 antibody predicts poor prognosis in patients with interstitial lung disease associated to systemic sclerosis

Autor: Michael Mahler, Karen Lorite-Gomez, Adriana Severino, V. Fonollosa-Pla, Maria Teresa Sanz-Martínez, Janire Perurena-Prieto, Alfredo Guillén-Del-Castillo, Chiara Bellocchi, Lorenzo Beretta, Eduardo L. Callejas-Moraga, Carmen Pilar Simeón-Aznar
Rok vydání: 2021
Předmět:
Adult
Male
medicine.medical_specialty
Settore MED/09 - Medicina Interna
systemic sclerosis
medicine.medical_treatment
anti-RNPC-3
anti-U11/U12 RNP
autoantibody
interstitial lung disease
030204 cardiovascular system & hematology
Gastroenterology
Disease-Free Survival
03 medical and health sciences
FEV1/FVC ratio
0302 clinical medicine
Rheumatology
Risk Factors
Internal medicine
Oxygen therapy
Epidemiology
medicine
Lung transplantation
Humans
Pharmacology (medical)
Autoantibodies
030203 arthritis & rheumatology
Scleroderma
Systemic
Proportional hazards model
business.industry
Interstitial lung disease
Autoantibody
Nuclear Proteins
RNA-Binding Proteins
Middle Aged
medicine.disease
Prognosis
Ribonucleoproteins
Small Nuclear
Survival Rate
Settore MED/16 - Reumatologia
Cohort
Female
business
Lung Diseases
Interstitial
Zdroj: Rheumatology (Oxford, England). 61(1)
ISSN: 1462-0332
Popis: Objective To analyse the prevalence, the clinical characteristics, the overall survival and the event-free survival (EFS) of SSc patients who express anti-U11/U12 RNP (RNPC-3) antibodies. Methods A total of 447 SSc patients from Barcelona (n = 286) and Milan (n = 161) were selected. All samples were tested using a particle-based multi-analyte technology. We compared anti-RNPC-3 positive and negative patients. Epidemiological, clinical features and survival were analysed. End-stage lung disease (ESLD) was defined if the patient developed forced vital capacity Results Nineteen of 447 (4.3%) patients had anti-RNPC-3 antibodies and interstitial lung disease (ILD) was more frequent (11, 57.9% vs 144, 33.6%, P =0.030) in individuals with anti-RNPC-3 antibodies. More patients reached ESLD in the positive group (7, 36.8% vs 74, 17.3%, P = 0.006), and a higher use of non-glucocorticoid immunosuppressive drugs was observed (11, 57.9% vs 130, 30.4%, P = 0.012). Anti-RNPC-3 positive patients had lower EFS, both in the total cohort (log-rank P =0.001), as well as in patients with ILD (log-rank P = 0.002). In multivariate Cox regression analysis, diffuse cutaneous subtype, age at onset, the presence of ILD or pulmonary arterial hypertension and the expression of anti-RNPC-3 positivity or anti-topo I were independently associated with worse EFS. Conclusion The presence of anti-RNPC-3 was associated with higher frequency of ILD and either ESLD or death. These data suggest anti-RNPC-3 is an independent poor prognosis antibody in SSc, especially if ILD is also present.
Databáze: OpenAIRE
Externí odkaz: